During a well-attended symposium on movement management in lung radiosurgery chaired by Pr. Volker Budach, M.D., Ph.D. Clinical study presented through the symposium demonstrated the benefits of CyberKnife radiosurgery in the treatment of principal early stage and metastatic lung tumor, including excellent disease control and preservation of quality of life. Related StoriesMD Anderson research reveals why chemotherapy medicines not effective for most pancreatic cancer patientsNew RNA test of blood platelets can be used to detect location of cancerCrucial modification in single DNA base predisposes children to intense form of cancer The Synchrony System is unique in its ability to correct for changes in a patient’s design of breathing in real-period, stated Dr.Contributions to the interpretation of data and the subsequent composing, reviewing, and amending of the manuscript were made by all authors. The first draft of the manuscript was prepared by the 1st and last authors and by the trial’s lead doctor at Novartis. No one who is not an author contributed to composing the manuscript. Letrozole or anastrozole did not have to be the most recent treatment before randomization, but progression or recurrence during receipt of the very most recent systemic therapy had to be documented before randomization. Other previous anticancer endocrine remedies and a single prior chemotherapy regimen for advanced disease were also allowed. Patients had to have at least 1 measurable lesion or mainly lytic bone lesions in the absence of measurable disease.